The medical treatment of erectile dysfunction

Drugs of Today

Volumn 32, Issue 6, 1996, Pages 483-499

  Benet, Alexandru E ^a   Rehman, Jamil ^a   Melman, Arnold ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; APOMORPHINE; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAN; FORSKOLIN; GLYCERYL TRINITRATE; ISOXSUPRINE; LEVODOPA; LINSIDOMINE; METHYSERGIDE; METHYSERGIDE MALEATE; MILRINONE; MINOXIDIL; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; OXYTOCIN; PAPAVERINE; PERGOLIDE; PHENOXYBENZAMINE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PROSTAGLANDIN E1; SELEGILINE; SEROTONIN AGONIST; SILDENAFIL; TRAZODONE; YOHIMBINE;

FLUSHING; HUMAN; IMPOTENCE; LACRIMATION; MALE; NAUSEA; PENIS ERECTION; PROSTATE CANCER; RESPIRATION DEPRESSION; REVIEW; SEXUAL DYSFUNCTION; VERTIGO; VOMITING;

EID: 0029826322     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993, 270: 83-7.
2. Benet, A.E., Melman, A. The epidemiology of erectile dysfunction. Urol Clin N Amer 1995, 22 (4): 699-709.
3. Benet, A.E., Sharaby, J.S., Melman, A. Male erectile dysfunction assessment and treatment options. Comp Ther 1994, 20 (12): 669-73.
4. Feldman, H.A., Goldstein, I., Hatzichristou, D., Krane, R., McKinley, J. Impotence and its medical and psychosocial correlates: Results of the Massachusetts male aging study. J Urol 1994, 151: 54.
5. Virag, R. Intracavernous injection of papaverine for erectile failure. Lancet 1982, 2: 938.
6. Brindley, G.S. Cavernosal alpha-blockade: A new technique for investigating and treating erectile impotence. Brit J Psychiat 1983, 143: 332.
7. Schiavi, R.C., Rehman, J. Sexuality and aging. Urol Clin N Amer 1995, 22 (4): 711-26.
8. Rehman, J., Benet, A.E., Melman, A. Penile revascularization. In: Mediguide in Urology. Carson, C.C. III (Ed.). Lawrence DellaCorte Publications, Inc.: New York 1996, 1-7.
9. Maeda, N., Matsuoka, N., Yamaguchi, I. Role of the dopaminergic, serotonergic and cholinergic link in the expression of penile erection in rats. Jpn J Pharmacol 1994, 66 (1): 59-66.
10. 1C receptor agonists in male rats: Relationship with dopaminergic and oxytocinergic transmission. Eur J Pharmacol 1994, 261 (1-2): 149-55.
11. Panegyres, P.K., Graham, S.J., Williams, B.K. et al. Sublingual apomorphine solution in Parkinson's disease. Med J Australia 1991, 155: 371-4.
12. Heaton, J.P., Morales, A., Adams, M.A., Johnston, B., El-Rashidy, R. Recovery of erectile function by the oral administration of apomorphine. Urology 1995, 45 (2): 200-6.
13. Finberg, J.P.M., Vardi, Y. Inhibitory effect of 5-hydroxytryptamine on penile erectile function in the rat. Brit J Pharmacol 1990, 101 (3): 698-702.
14. Grossman, E., Rosenthal, T., Peleg, E., Holmes, C., Goldstein, D.S. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol 1993, 22 (1): 22-6.
15. Sonda, L.P., Mazo, R., Chancellor, M.B. The role of yohimbine for the treatment of erectile impotence. J Sexual Marital Ther 1990, 16 (1): 15-21.
16. Morales, A., Heaton, J.P., Johnston, B., Adams, M. Oral and topical treatment of erectile dysfunction. Present and future. Urol Clin N Amer 1995, 22 (4): 879-86.
17. Steers, W.D., Albo, M., van Asselt, E. Effects of serotonergic agonists on micturition and sexual function in the rat. Drug Dev Res 1992, 27 (4): 361-75.
18. 1A receptor involvement in yawning and penile erections induced by apomorphine, physostigmine and mCPP in rats. Psychopharmacology 1995, 120 (4): 376-83.
19. 1A Receptor blockade increases penile erections induced by indirect serotonin agonists. NeuroReport 1993, 5 (3): 229-30.
20. Steers, W.D., De Groat, W.C. Effects of m-chlorophenylpiperazine on penile and bladder function in rats. Amer J Physiol 1989, 257 (6): R1441-9.
21. Kurt, U., Ozkardes, H., Altug, U., Germiyanoglu, C., Gurdal, M., Erol, D. The efficacy of anti-serotoninergic agents in the treatment of erectile dysfunction. J Urol 1994, 152 (2, Pt 1): 407-9.
22. Bondil, P. The combination of oral trazodonemoxisylyte: Diagnostic and therapeutic value in impotence. Report of 110 cases. Prog Urol 1992, 2 (4): 671-4.
23. Montorsi, F., Strambi, L.F., Guazzoni, G. et al. Effect of yohimbine + trazodone in psychogenic impotence: A randomized double-blind, placebo controlled study. Urology 1994, 44: 732.
24. Lance, R., Albo, M., Costabile, R.A., Steers, W.D. Oral trazodone as empirical therapy for erectile dysfunction: A retrospective review. Urology 1995, 46 (1): 117-20.
25. van Ahlen, H., Piechota, H.J., Kias, H.J., Brennemann, W., Klingmuller, D. Opiate antagonists in erectile dysfunction: A possible new treatment option? Results of a pilot study with naltrexone. Eur Urol 1995, 28 (3): 246-50.
26. 2 receptor stimulation on excessive grooming, penile erection and plasma oxytocin concentrations. Eur J Pharmacol 1992, 229 (1): 9-14.
27. Wagner, G., Lacy, S., Lewis, R., Zorgniotti, A. Buccal phentolamine: A pilot trial for male erectile dysfunction at three separate clinics. Int J Impotence Res 1994, Suppl. 1: D78.
28. Gwinup, G. Oral phentolamine in non-specific erectile insufficiency. Ann Intern Med 1988, 109: 162.
29. Zorgniotti, A.W., Lizza, E.F. Effect of large doses of nitric oxide precursor, L-arginine, on erectile failure. Int J Impotence Res 1994, 6: 33.
30. Anderson, D.C. Jr., Seifert, C.F. Topical nitrate treatment of impotence. Ann Pharmacother 1993, 27 (10): 1203-5.
31. Meyhoff, H.H., Rosenkilde, P., Bodker, A. Non-invasive management of impotence with transcutaneous nitroglycerin. Brit J Urol 1992, 69 (1): 88-90.
32. Nunez, B.D., Anderson, D.C. Jr. Nitroglycerin ointment in the treatment of impotence. J Urol 1993, 150 (4): 1241-3.
33. Pastorini, S., Cocimano, V., Pugno, E., Marten Perolino, R. Topical treatment of erectile dysfunction. Possibilities and perspectives. Arch Ital Urol Androl 1995, 67 (5): 299-302.
34. Porst, H. Nitroglycerin ointment in erectile impotence? Deutsch Med Wochenschr 1993, 118 (6): 203.
35. Sonksen, J., Biering-Sorensen, F. Transcutaneous nitroglycerin in the treatment of erectile dysfunction in spinal cord injured men. Paraplegia 1992, 30 (8): 554-7.
36. Moralis, A., Condra, M.S., Owen, J.E., Fenemore, J., Surridge, D.H. Oral and transcutaneous pharmacological agents in the treatment of impotence. Urol Clin N Amer 1988, 15: 87-93.
37. Heaton, J.P.W., Morales, A., Owen, J.A., Fenemore, J. Topical gliceriltrinitrate causes measurable penile arterial dilatation in impotent men. J Urol 1990, 143: 729.
38. Owen, J.A., Saunders, F., Harris, C. et al. Topical nitroglycerin: A potential treatment for impotence. J Urol 1989, 141: 546-48; 1990, 143: 586.
39. Owen, J.A., Saunders, F., Harris, C. et al. Topical nitroglycerin: A potential treatment for impotence. J Urol 1989, 141: 546-48; 1990, 143: 586.
40. Cavallini, G. Minoxidil versus nitroglycerine: A prospective, double-blind, controlled trial in transcutaneous therapy for organic impotence. Int J Impotence Res 1994, 6 (4): 205-12.
41. Beretta, G., Saltarelli, O., Marzotto, M., Zanollo, A., Re, B. Transcutaneous minoxidil in the treatment of erectile dysfunctions in spinal cord injured men. Acta Eur Fertil 1993, 24 (1): 27-30.
42. Cecchi, M., Sepich, C.A., Felipetto, R. et al. Vacuum constriction device and topical minoxidil for management of impotence. Arch Esp Urol 1995, 48 (10): 1058-9.
43. Christ, G.J., Spray, D.C., Brink, P.R. Characterization of K currents in cultured human corporal smooth muscle cells. J Androl 1993, 14 (5): 319-28.
44. + (KCa) channel in cultured human corporal smooth muscle cells. J Urol 1995, 153 (3, Pt 1): 818-25.
45. Padma-Nathan, H., Keller, T., Poppiti, R., Lue, T., Tam, P., Place, V. Hemodynamic effects of intraurethral alprostadil: The medicated urethral system for erection (MUSE). J Urol 1994, 151 (5): 469 (Abst).
46. Padma-Nathan, H., Bennett, A., Gesundheil, N. et al. Treatment of erectile dysfunction by the medicated urethral system (MUSE). J Urol 1995, 153: 472.
47. 1 in erectile dysfunctions. Clin Invest 1994, 72: 139-49.
48. Linet, O. Upjohn FDA submission for Caverject. PDR formulary information and teaching material, 1995.
49. Dennis, M., Benet, A.E., Melman, A. Patient preference in the treatment of erectile dysfunction. J Urol 1996, 155 (5): 469A.
50. Lomas, G.M., Jarow, J.P. Risk factors for papaverine-induced priapism. J Urol 1992, 147 (5): 1280-1.
51. Andersson, K.E., Holmquist, F., Wagner, G. Pharmacology of drugs used for the treatment of erectile dysfunction and priapism. Int J Impotence Res 1991, 3: 155-72.
52. Kim, E.D., El-Rashidy, R., McVary, K. Papaverine topical gel for treatment of erectile dysfunction. J Urol 1995, 153: 361.
53. Anonymous. Alprostadil for erectile impotence. Drug Ther Bull 1995, 33 (8): 61-2.
54. Hedlund, H., Andersson, K.E. Contraction and relaxation induced by some prostanoids in isolated human penile erectile tissue and cavernous artery. J Urol 1985, 134: 1245.
55. Trigo-Rocha, F., Hsu, G.L., Donatucci, C.F., Lue, T.F. The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic and noncholinergic neurotransmission in canine penile erection. J Urol 1993, 149 (4): 872-7.
56. Palmer, L.S., Valcic, M., Melman, A., Giraldi, A., Wagner, G., Christ, G.J. Characterization of cyclic AMP accumulation in cultured human corpus cavernosum smooth muscle cells. J Urol 1994, 152 (4): 1308-14.
57. Trigo-Rocha, F., Aronson, W.J., Hohenfellner, M. et al. Nitric oxide and cGMP: Mediators of pelvic nerve-stimulated erection in dogs. Amer J Physiol 1993, 264 (2, Pt 2): H419-22.
58. Trigo-Rocha, F., Hsu, G.L., Donatucci, C.F., Martinez-Pineiro, L., Lue, T.F., Tanagho, E.A. Intracellular mechanism of penile erection in monkeys. Neurourol Urodyn 1994, 13 (1): 71-80.
59. Miller, M.A., Morgan, R.J. Eicosanoids, erections and erectile dysfunction. Prostagland Leuk Essent Fatty Acids 1994, 51 (1): 1-9.
60. Christ, G.J. The penis as a vascular organ. The importance of corporal smooth muscle tone in the control of erection. Urol Clin N Amer 1995, 22 (4): 727-45.
61. Pickard, R.S., Powell, P.H., Zar, M.A. Nitric oxide and cyclic GMP formation following relaxant nerve stimulation in isolated human corpus cavernosum. Brit J Urol 1995, 75 (4): 516-22.
62. Cahn, D., Melman, A., Valcic, M., Christ, G. Forskolin: A promising new adjunct to intracavernous pharmacotherapy. J Urol 1996, 155: 1789-94.
63. 1: Introductory remarks. In: Atherosclerosis. Sinzinger, H., Rogatti, E. (Eds.). Springer-Verlag: New York 1986, 3-7.
64. 2+ in cultured human corporal smooth muscle cells. Amer J Physiol 1992, 263 (2, Pt 1): C373-83.
65. Zhao, W., Christ, G.J. Endothelin-1 as a putative modulator of erectile dysfunction. II. Calcium mobilization in cultured human corporal smooth muscle cells. J Urol 1995, 154 (4): 1571-9.
66. -1 alters endothelin-1 (ET-1)-induced calcium transients in cultured human corporal smooth muscle cells. J Urol 1996, 155(5): Abst 1245.
67. Christ, G.J., Maayani, S., Valcic, M., Melman, A. Pharmacological studies of human erectile tissue: Characteristics of spontaneous contractions and alterations in α-adrenoceptor responsiveness with age and disease in isolated tissues. Brit J Pharmacol 1990, 101 (2): 375-81.
68. Taub, H.C., Lerner, S.E., Melman, A., Christ, G.J. Relationship between contraction and relaxation in human and rabbit corpus cavernosum. Urology 1993, 42 (6): 698-704.
69. Lerner, S.E., Melman, A., Christ, G.J. A review of erectile dysfunction: New insights and more questions. J Urol 1993, 149 (5, Pt 2): 1246-55.
70. Christ, G.J., Valcic, M., Gondre, M.C. Augmentation in the kinetic characteristics of phenylephrine- and 5-hydroxytryptamine-induced contractions in the isolated rat aorta following eight weeks of STZ-diabetes. Life Sci 1994, 55 (10): 807-14.
71. Roy, A.C., Adaikin, P.G., Sen, D.H., Ratnam, S.S. Prostaglandin 15-hydroxydehydrogenase activity in human penile corpora cavernosa and its significance in prostaglandin-mediated erections. Brit J Urol 1989, 64: 180.
72. 1 in patients with peripheral arterial disease. Prostaglandins 1991, 41: 225.
73. Van Ahlen, H., Peskar, B., Sticht, G., Hertfelder, H.J. Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. J Urol 1994, 151: 364A.
74. Padma-Nathan, H. The efficacy and synergy of polypharmacotherapy in primary and salvage therapy of vasculogenic erectile dysfunction. Int J Impotence Res 1990, 2 (2): 257.
75. Bennett, A.H., Carpenter, A.J., Barada, J.H. An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991, 146: 1564.
76. 1 diluted solution: Preparation technique and stability evaluation. Int J Impotence Res 1993, 5 (1): 43-5.
77. Hall, S., Honig, S., Payton, T. et al. Use of atropine sulphate in the pharmacologic erections: Initial experience with one year follow-up in the United States. J Urol 1992, 147: 265A.
78. Stief, C.G., Uckert, S., Truss, M.C. et al. Cyclic nucleotide PDE isoenzymes in human cavernous smooth muscle. Int J Impotence Res 1995, 7 (Suppl. 1): 6.
79. Roy, J.B., Petrone, R.L., Said, S.I. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection. J Urol 1990, 143: 302-4.
80. Gerstenberg, T.C., Metz, P., Ottesen, B., Fahrenkrug, J. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure. J Urol 1992, 147 (5): 1277-9.
81. Kiely, E.A., Bloom, S.R., Williams, G. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Brit J Urol 1989, 64: 191-4.
82. Stief, C.G., Holmquist, F., Djamilian, M., Krah H., Andersson, K.E., Jonas, U. Preliminary results with the nitric oxide donor linsidomine chlorhydrate in the treatment of human erectile dysfunction. J Urol 1992, 148 (5): 1437-40.
83. Truss, M.C., Becker, A.J., Djamilian, M.H., Stief, C.G., Jonas, U. Role of the nitric oxide donor linsidomine chlorhydrate (SIN-1) in the diagnosis and treatment of erectile dysfunction. Urology 1994, 44 (4): 553-6.
84. Wegner, H.E., Knispel, H.H. Effect of nitric oxide-donor, linsidomine chlorhydrate, in treatment of human erectile dysfunction caused by venous leakage. Urology 1993, 42 (4): 409-11.
85. 1 versus linsidomine chlorhydrate in erectile dysfunction. Urol Int 1994, 53 (4): 214-6.
86. 1. J Urol 1992, 148 (4): 1181-3.
87. Armstrong, D.K., Convery, A., Dinsmore, W.W. Intracavernosal papaverine and phentolamine for the medical management of erectile dysfunction in a genitourinary clinic. Int J STD & AIDS 1993, 4 (4): 214-6.
88. 1 with other intracavernous injections. Eur Urol 1994, 26 (4): 319-21.
89. Chao, R., Clowers, D.E. Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction. Arch Phys Med Rehab 1994, 75 (3): 276-8.
90. 1 versus papaverine-phentolamine alone for intracorporeal injection therapy: A clinical double-blind study. J Urol 1995, 154 (3): 1017-9.
91. 1, papaverine and phe̊ntolamine in nonresponders to high papaverine plus phentolamine doses [see comments]. J Urol 1996, 155 (3): 913-4.
92. 1 on penile erection and erectile failure. J Urol 1987, 137: 1010.
93. Valdevenito, R., Melman, A. Intracavernous self-injection pharmacotherapy program: Analysis of results and complications. Int J Impotence Res 1994, 6 (2): 81-91.
94. 1. Int J Impotence Res 1995, 7 (2): 83-90.
95. Govier, F.E., McClure, R.D., Weissman, R.M., Gibbons, R.P., Pritchett, T.R., Kramer-Levien, D. Experience with triple-drug therapy in a pharmacological erection program. J Urol 1993, 150 (6): 1822-4.
96. 1 plus procaine in the treatment of erectile dysfunction. J Urol 1994, 152: 1108.
97. Moriel, E.Z., Rajfer, J. Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction. J Urol 1993, 149: 1299.
98. Muruve, N., Hosking, D.H. Intracorporeal phenylephrine in the treatment of priapism. J Urol 1996, 155 (1): 141-3.
99. 1, and saline in primates. J Urol 1989, 142: 403.
100. Kolaja, G.J., Kirton, K.T. Toxicology studies with alprostadil: The role of alprostadil in the diagnosis and treatment of erectile dysfunction. Excerpta Medica: Princeton 1993.
101. 1 suppresses the induction of collagen synthesis by transforming growth factor beta-1 in human corpus cavernosum smooth muscle. J Urol 1995, 153: 826.
102. Marshall, G.A., Breza, J., Lue, T.F. Improved hemodynamic response after long-term intracavernous injection for impotence. Urology 1994, 43 (6): 844.
103. 1: Long-term results of an international multi-center study according to the GCP standard. Int J Impotence Res 1994, 6 (1): D108.
104. 1 in erectile failure: A survey of worldwide experience. J Urol 1996, 155 (3): 802-15.
105. Chevalier, S., Bleau, G., Roberts, K.D., Chapdelaine, A. Non-steroidal serum factors Involved in the regulation of the proliferation of canine prostatic epithelial cells in culture. Prostate 1984, 5: 503.
106. Vermeulen, A. Androgens in the aging male. J Clin Endocrinol Metab 1991, 73: 2.
107. Bhere, H.M., Bohmeyer, J., Nieschlag, E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol 1994, 41: 341.
108. Holmang, S., Marin, P., Lindstedt, G., Hadelin, H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 1993, 23: 99.
109. Mulligan, T., Schmitt, B. Testosterone for erectile failure. J Gen Intern Med 1993, 8 (9): 51.
110. Tenover, J.S. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992, 75(4): 1092-8.
111. Friedl, K.E., Hannan, C.J. Jr., Jones, R.E., Plymate, S.R. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism 1990, 39(1): 69-74.
112. Marin, P., Holmang, S., Jonsson, L. et al. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men. Int J Obes Relat Metab Disord 1992, 16(12): 991-7.
113. Barrett-Connor, E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992, 117(10): 807-11; 1992, 117(10): 871-2; 1993, 118(10): 826.
114. Barrett-Connor, E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992, 117(10): 807-11; 1992, 117(10): 871-2; 1993, 118(10): 826.
115. Barrett-Connor, E. Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med 1992, 117(10): 807-11; 1992, 117(10): 871-2; 1993, 118(10): 826.
116. Wallace, R.B., Hunninghake, D.B., Chambless, L.E., Heiss, G., Wahl, P., Barrett-Connor, E. A screening survey of dyslipoproteinemias associated with prescription drug use. The Lipid Research Clinics Program Prevalence Study. Circulation 1986, 73(1, Pt 2): 170-9.
117. De Lignieres, B. Transdermal dihydrotestosterone treatment of 'andropause'. Ann Med 1993, 25(3): 235-41.
118. Soe, K.L., Soe, M., Gluud, C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992, 12(2): 73-9.
119. Gooren, L.J. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994, 15(3): 212-5.
120. Conway, A.J., Boylan, L.M., Howe, C., Ross, G., Handelsman, D.J. Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 1988, 11(4): 247-64.
121. McClure, R.D., Oses, R., Ernest, M.L. Hypogonadal impotence treated by transdermal testosterone. Urology 1991, 37(3): 224-8.